Literature DB >> 31692925

Specific death of ALT cells through TSPYL5 depletion.

Eloïse Claude1, Harikleia Episkopou1, Anabelle Decottignies1.   

Abstract

Some tumors acquire replicative immortality by activating an ALTernative telomerase-independent telomere maintenance mechanism. ALT offers interesting therapeutic perspectives but lacks any known specific targets. We discovered a crucial role for TSPYL5 (Testis-Specific Y-encoded-Like Protein 5) in keeping ALT cell viability by protecting POT1 (Protection Of Telomeres 1) from proteasomal degradation.
© 2019 Taylor & Francis Group, LLC.

Entities:  

Keywords:  ALTernative mechanism of telomere maintenance; POT1 shelterin; TSPYL5; USP7

Year:  2019        PMID： 31692925      PMCID： PMC6816424          DOI： 10.1080/23723556.2019.1651603

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  10 in total

1.  TSPYL5 suppresses p53 levels and function by physical interaction with USP7.

Authors:  Mirjam T Epping; Lars A T Meijer; Oscar Krijgsman; Johannes L Bos; Pier Paolo Pandolfi; René Bernards
Journal:  Nat Cell Biol       Date:  2010-12-19       Impact factor: 28.824

Review 2.  Molecular mechanisms of activity and derepression of alternative lengthening of telomeres.

Authors:  Hilda A Pickett; Roger R Reddel
Journal:  Nat Struct Mol Biol       Date:  2015-11-04       Impact factor: 15.369

3.  Highly Aggressive Metastatic Melanoma Cells Unable to Maintain Telomere Length.

Authors:  Nikenza Viceconte; Marie-Sophie Dheur; Eva Majerova; Christophe E Pierreux; Jean-François Baurain; Nicolas van Baren; Anabelle Decottignies
Journal:  Cell Rep       Date:  2017-06-20       Impact factor: 9.423

4.  Probing PML body function in ALT cells reveals spatiotemporal requirements for telomere recombination.

Authors:  Irena Draskovic; Nausica Arnoult; Villier Steiner; Silvia Bacchetti; Patrick Lomonte; Arturo Londoño-Vallejo
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-26       Impact factor: 11.205

5.  Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes.

Authors:  Christopher M Heaphy; Andrea P Subhawong; Seung-Mo Hong; Michael G Goggins; Elizabeth A Montgomery; Edward Gabrielson; George J Netto; Jonathan I Epstein; Tamara L Lotan; William H Westra; Ie-Ming Shih; Christine A Iacobuzio-Donahue; Anirban Maitra; Qing K Li; Charles G Eberhart; Janis M Taube; Dinesh Rakheja; Robert J Kurman; T C Wu; Richard B Roden; Pedram Argani; Angelo M De Marzo; Luigi Terracciano; Michael Torbenson; Alan K Meeker
Journal:  Am J Pathol       Date:  2011-09-01       Impact factor: 4.307

Review 6.  Regulation of USP7: A High Incidence of E3 Complexes.

Authors:  Robbert Q Kim; Titia K Sixma
Journal:  J Mol Biol       Date:  2017-06-04       Impact factor: 5.469

7.  Protection of telomeres through independent control of ATM and ATR by TRF2 and POT1.

Authors:  Eros Lazzerini Denchi; Titia de Lange
Journal:  Nature       Date:  2007-08-08       Impact factor: 49.962

8.  TSPYL5 Depletion Induces Specific Death of ALT Cells through USP7-Dependent Proteasomal Degradation of POT1.

Authors:  Harikleia Episkopou; Aurélie Diman; Eloïse Claude; Nikenza Viceconte; Anabelle Decottignies
Journal:  Mol Cell       Date:  2019-07-02       Impact factor: 19.328

9.  Alternative Lengthening of Telomeres is characterized by reduced compaction of telomeric chromatin.

Authors:  Harikleia Episkopou; Irena Draskovic; Amandine Van Beneden; Gaëlle Tilman; Marina Mattiussi; Matthieu Gobin; Nausica Arnoult; Arturo Londoño-Vallejo; Anabelle Decottignies
Journal:  Nucleic Acids Res       Date:  2014-02-05       Impact factor: 16.971

10.  The shelterin component TPP1 is a binding partner and substrate for the deubiquitinating enzyme USP7.

Authors:  Ivo Zemp; Joachim Lingner
Journal:  J Biol Chem       Date:  2014-08-29       Impact factor: 5.486
  10 in total
  1 in total

1.  Detection of alternative lengthening of telomeres mechanism on tumor sections.

Authors:  Eloïse Claude; Guillaume de Lhoneux; Christophe E Pierreux; Etienne Marbaix; Maëlle de Ville de Goyet; Cécile Boulanger; An Van Damme; Bénédicte Brichard; Anabelle Decottignies
Journal:  Mol Biomed       Date:  2021-10-20
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.